Stephen Fesik

Research from the lab of Bill Tansey and other collaborators tested protein inhibitors called WINi against a panel of cancer cells and found that they have strong action against blood cancers and synergize with an FDA-approved cancer drug. Read More

Researchers in the lab of Stephen Fesik, Orrin H. Ingram II Chair in Cancer Research, have added BI-0474 as the second molecule co-discovered by Vanderbilt to the open science portal opnMe.com, an initiative being driven by biopharmaceutical company Boehringer Ingelheim. Read More

A collaborative project between William Tansey and Stephen Fesik has laid the foundation for pre-clinical and clinical trials for rare childhood tumors that are diagnosed in 25 children per year in the United States. Read More

Stephen Fesik’s discovery of a cancer-targeting molecule has been made freely accessible through opnMe for global researchers to advance research into cancer therapeutics. Read More

Stephen Fesik and colleagues have uncovered more details about how a crucial component of RAS proteins, which trigger about a third of all tumors, work. This finding will help advance the discovery of new cancer therapies. Read More

New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers. Read More

Vanderbilt University has been selected as one of seven Dedicated Centers in the nation for the next phase of the Chemical Biology Consortium (CBC), a national network of scientists on the leading edge of cancer drug discovery. Read More

A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures. Read More

Vanderbilt University researchers have discovered a cleft in a chromosome-binding protein that may hold the key to stopping most cancers in their tracks. Read More

The Lustgarten Foundation has awarded a $1.5 million Research Investigator Grant to Stephen Fesik, Ph.D., professor of Biochemistry, Pharmacology and Chemistry, for research designed to discover new drugs for the treatment of pancreatic cancer. Read More

Vanderbilt researchers have discovered small molecules that turn off cancerous Ras signals in a new way. Read More

The April program for My Health Chat will be the promising world of cancer drug discovery. Panelists will be Lawrence Marnett, director of the Vanderbilt Institute of Chemical Biology, and Stephen Fesik, director of drug discovery at Vanderbilt-Ingram Cancer Center. They will discuss… Read More

Vanderbilt University’s acquisition of a 900 megahertz nuclear magnetic resonance (NMR) spectrometer will accelerate studies on cancer and Alzheimer’s disease. Read More

Seven Vanderbilt University faculty members have been elected fellows of the American Association for the Advancement of Science, an honor bestowed upon them by their AAAS peers. They are among 503 AAAS members from around the country who achieved this honor because of their distinguished efforts to advance science… Read More